Базисные подходы к оценке эффективности лечения синдрома спастичности у детей с детским церебральным параличом препаратами ботулинического токсина типа А

Рассмотрены основные шкалы и тесты, применяемые в клинических исследованиях и практической медицине при оценке эффективности терапии синдрома спастичности препаратами ботулинического токсина типа А у детей с детским церебральным параличом. Приведены сведения о рекомендованных методах оценки, предложены шкалы, которые могут быть использованы при проведении оценки эффективности, проведён анализ их информативности и чувствительности.

ботокс, Диспорт, ботулинический токсин типа А, ДЦП, Шкала оценки глобальных моторных функций, шкала Эшворта, Шкала оценки результатов лечения, дети-инвалиды, модифицированная шкала Тардье

1. Дутикова Е.М., Лильин Е.Т. Ботулотоксин типа А (Диспорт) в лечении детского церебрального паралича. Фарматека 2007; 7 (142): 37-42

2. Батышева T.T. и dp. Лечение спастичности у детей с церебральными параличами. Методические рекомендации №15, М.: 2011

3. Chambers H.G. Muscle Nerve 1997; Suppl. 6, P. 121129.

4. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005; 63: 180-185.

5. Brin M. F., Hallett M., Jankovic J. Scientific and therapeutic aspects of botulinum toxic, NY: Wilkins, 2002; 507.

6. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-1049.

7. Delgado M.R., Hirtz D., Aisen M., Ashwal S., Fehlings D.L., McLaughlin J., Morrison L.A., Shrader M.W., Tilton A., Vargus-Adams J. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010; 74 (4): 336-343.

8. Heinen F., Molenaers G., Fairhurst C. et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006; 10: 5-6: 215-225.

9. Miller G., Clark G.D., The Cerebral Palsies. Causes, Consequences and Management / Eds G. Miller, G. О. Clark. - Boston: Butterworth Heinemann, 1998.

10. Eams N. W. A., Barker R., Gracham К. et al. The effect of botulinum toxin type А оn gastrocnemius length: magnitude and duration of response. Dev Med Child Neural 1999; 41: 226-232.

11. Hodgkinson I. Neurosurgical treatment of spasticity: indications in children/ Hodgkinson I., Sindou MM Neurochirurgie 2003 May; 49 (2-3 Pt 2): 408-412.

12. Heinen F., Desloovere K., Schroeder A.S. et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010; 14: 1: 45-66.

13. Hanna S.E., Bartlett D.J., Rivard L.M., Russell D.J. Reference curves for the Gross Motor Function Measure: Percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther 2008; 88 (5): 596-607.

14. Gorter J.W., Rosenbaum P.L., Hanna S.E., Palisano R.J., Bartlett D.J., Russell D.J., Walter S.D., Raina P., Galuppi B.E., Wood E. Limb distribution, motor impairment, and functional classification of cerebral palsy. Dev Med Child Neurol 2004; 46 (7): 461-467.

15. Eliasson A.C., Burtner P. Improving hand function in children with cerebral palsy. 1st edn. Mac. Keith Press. 2008.

16. Eliasson A.C., Krumlinde-Sundholm L., Rosblad B., Beckung E., Arner M., Ohrvall A.M., Rosenbaum P. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006; 48 (7): 549-554.

17. Carnahan K.D., Arner M., Hgglund G. Association between gross motor function (GMFCS) and manual ability (MACS) in children with cerebral palsy. A population-based study of 359 children. BMC Muscul Dis 2007; 8: 50.

18. Fehlings D., Novak I., Berweck S., Hoare B., Stott N.S., Russo R.N. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hyper-tonicity: international consensus statement. Eur J Neurol 2010; 17 2: 38-56.

19. Lowe K., Novak L., Cusich A. Low-dose / high-concentration localized bo-tulinum toxin A improves upper limb movement and function in children with he-miplegic cerebral palsy. Dev Med Child Neurology 2006; 48: 170-175.

20. Speth L.A., Leffers P., Janssen-Potten Y.J. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 2005; 47: 468-473.

21. Kawamura A., Campbell K., Lam-Damji S., Fehlings D. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 2007; 49: 331-337.

22. Koman L.A., Mooney J.F., Smith B. et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993; 4: 489-495.

23. Read H.S., Hillmann S.J., Hazlewood M.E. et al. The Edinburgh Visual Gait Analysis Interval Testing (GAIT) scale. Gait Posture 1999; 10: 63.

24. Flett P.J., Stern L.M., Waddy H. et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999; 35: 71-77.

25. Haley S., Coster W., Ludlow L., Haltiwanger J., Andrellos P. Pediatric Evaluation of Disability Inventory (PEDI). Boston, Mass: New England Medical Centre Hospitals. 1992.

26. Eams N. W. A., Barker R., Gracham К. et al. The effect of botulinum toxin type А оп gastrocnemius length: magnitude and duration of response. Dev Med Child Neural 1999; 41: 226-232.

27. Richardson A. A randomized, double-blind, placebo-controlled study to compare the efficacy and safety of Dysport with placebo in lover limb muscle spasticity in patients with spastic cerebral palsy. 2000.

28. Baker et al. Dysport in Dynamic Equinus R Dev Med Child Neurol 2002; 44: 666-675.

29. Moore et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71; 122-128.

30. Press Release. Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults, 26 January 2015.

31. Steenbeek D. et al. Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. Dev Med Child Neurol 2007; 49: 550-556.

32. Батышева T.T., Гузева В.Ию, Быкова О.В., Шиошвили B.A., Ногова Е.В., Флёрис Л. В. Axадoва Л.Я., Шатилова H.H., Квасова О.В., Сметажикова- Платонова A.H. Лечение и реабилитация детей со спастическими формами церебрального паралича. Методические рекомендации № 26. М.: 2016.

33. Mutlu A., Livanelioglu A., Gunel M. K. Reliability of ashworth and modified ashworth scales in children with spastic cerebral palsy. BMC Musculoskeletal Disorders 2008; 9: 44.

34. Helders P.J.M., Raoul H., Engelbert H., Custers J.W.H., Gorter J.W., Takken T., Van Der Net J. Creating and being created: the changing panorama of pediatric rehabilitation. Pediatr Rehabil 2003; 6: 1 (Jan-Marc 2003): (5-12): 1363-8491.

35. Куренков А.Л., Бурсагова Б.И., Кузенкова Л.М., Петрова C.A. Применение ботулинического токсина типа А при спастических формах детского церебрального паралича. Эффективная фармакотер. Педиатрия 2013; 1.

36. Rosnow R.L., Rosemthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: General procedures for research consumers. Pyschol Methods 1996; 1: 331-340.

37. Moore A.P., Ade-Hall R.A., Smith C.T., Rosenbloom L., Walsh H.P.J., Mohamed K., Williamson P.R. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71: 122-128.

38. El-Maksoud G.M., EL-Sherbini M.H. Effect of botulinum toxin with rehabilitation therapy on standing in children with spastic diplegic cerebral palsy. Med J Cairo Univ 2010; 78: 2: 573-583.

39. Bjornson K. Botulinum Toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007 Jul; 120 (1): 49-58.

40. Park E.S. et al. The effect of botulinum toxin type a injection into the gastrocnemius muscle on sit-to-stand transfer in children with spastic diplegic cerebral palsy. Clin Rehabil 2006; 20 (8): 668-674.

41. Liu J.-J., Ji S.-R., Wu W.-H., Zhang Y., Zeng F.-Y., Li N.-L. The relief effect of botulinum toxin-a for spastic iliopsoas of cerebral palsy on children, Eur Rev Med Pharmacol Sci 2014; 18 (21): 3223-3228.

42. Wallen M., O'Flaherty S.J., Waugh M.C. Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial., Arch Phys Med Rehabil 2007; 88: 1-10.